Hadassah Ein Karem Campus: Inauguration of a New Radiopharmaceutical Manufacturing Facility
A novel facility for the research and development of radiopharmaceuticals has been inaugurated in Hadassah Ein Kerem Hospital following a 13 million NIS investment. The facility is located four stories underground and has 2.5-meter-thick concrete walls.
Ein Karem Campus: New Drug Development Rooms Inaugurated
New Radioactive Drug Production Rooms Inaugurated at Hadassah Ein Kerem Campus The most advanced rooms in Israel for developing and producing radiopharmaceuticals were inaugurated at the Hadassah Ein Karem campus, after an investment of 13 million shekels. In a ceremony attended by Hadassah’s CEO, Prof. Zeev Rotstein, the chairman of S.R.Y., Avi Balashnikov, leading figures […]
Journey to the Core of the Earth: The Fortified Particle Accelerator Fighting Cancer
In a secluded bunker located under Hadassah Ein-Kerem hospital resides an exceptional particle accelerator called “cyclotron”. Dror Foyer visited the sanctum sanctorum in an attempt to unveil the mysteries of radioactive drug (AKA radiopharmaceutical) production. Similar to guided missiles, these unique radiopharmaceuticals can target various pathologies but are most commonly used in cancer. Following their injection into patients, they enable imaging and/or treatment of various tumors.
Launch of New <sup>18</sup>F-PSMA-1007 Production Line
S.R.Y. has successfully developed and implemented a production line for 18F-PSMA-1007, a novel fluorine-18 labeled PSMA (prostate specific membrane antigen) ligand facilitating the diagnosis of prostate cancer (PC) and its metastases. in the world for prostate cancer imaging Since its introduction in 2011, 68Ga-PSMA-11 has been commonly used for PSMA-targeted imaging, mostly in Europe and […]
First in Israel: Test to Identify Risk of Developing Alzheimer’s Disease
For the first time: Brain imaging will identify the protein associated with the risk of suffering from the disease. The test is performed at Hadassah Jerusalem. For the first time in Israel: A simple, non-invasive brain imaging test will identify the risk of developing Alzheimer’s disease. The test can detect the protein associated with the […]
Hadassah rolls out non-invasive brain test to help prevent Alzheimer’s en
Hadassah has a six-year contract to exclusively produce and market Vizamyl. A new medical test that could help doctors prevent the onset of Alzheimer’s disease – and discover new and better treatments for it – is now being conducted in Israel. Hadassah Ein Kerem announced that it’s SRY subsidiary has contracted with General Electric (GE) […]
S.R.Y. Is Granted GMP Certification
The Ministry of Health has granted S.R.Y. a GMP certification for a radiopharmaceutical production line. As part of our core values, we have committed ourselves to delivering a final product that is effective, safe to use, and of the highest quality. This means that the end user, whether a patient, a treating physician, or a […]
<sup>18</sup>F-NOTA-TIDE: Somatostatin analog, labeled with fluorine-18
S.R.Y. Medical Services is proud to announce, for the first time in Israel, the launch of 18F-NOTA-OCTREOTIDE, a somatostatin analog labeled with fluorine-18, designed for PET imaging of neuroendocrine tumors (NET). 68Ga-DOTA-TATE 18F-NOTA-TIDE 68min 110min Half life Generator Cyclotron Production 836keV 249keV Mean positron energy 85-86%a, b 83-99%a, b Detection rate a Pauwels E., et […]
PET <sup>18</sup>F-mFBG imaging of hNET-expressing neural crest tumors
The human norepinephrine transporter (hNET) is a transmembrane protein responsible for the uptake of norepinephrine into noradrenergic synaptic terminals of the central and peripheral nervous systems and in adrenal chromaffin cells. Notably, several neural crest tumors, such as neuroblastoma, paraganglioma and pheochromocytoma, are often characterized by high hNET expression1. Iodine-123 and iodine-131 labeled meta-iodobenzylguanidine ([123/131I]mIBG), […]
